Ubiquigent
@ubiquigent
Followers
363
Following
9
Media
111
Statuses
275
Ubiquigent enables the discovery and development of novel #deubiquitinase (DUB) modulators as powerful new #therapeutics
Dundee, UK
Joined February 2012
We are in the process of transferring the Ubiquigent brand to a new owner, who may, in due course, provide future support to UPS research worldwide. We wish you all well with your future research and scientific endeavours.
0
0
0
To all our valued customers, collaborators, partners and suppliers, we regret to inform you that Ubiquigent Limited is no longer providing access to high-quality, validated reagents or services to support your Ubiquitin Proteasome System (UPS) related research.
0
0
1
@o2h_discovery will provide Ubiquigent with access to chemists and associated expertise to support its development of a novel portfolio of DUB-targeting compounds to enable the development of DUB-based therapeutics in partnership with its pharma and biotech partners.
0
1
2
We’re excited to announce that we have won an o2h Kickstarter Award. #enabling #partnerships #DUB #deubiquitinase.@o2h_discovery
1
0
3
Last call to submit to our DUBprofiler Open Access Initiative!.Submit your DUB inhibitors for screening - gain insights into your non-proprietary compounds’ potency & selectivity to ensure your research & #drugdiscovery programmes have a strong foundation: services@ubiquigent.com
0
1
1
Interested in learning more about the potency & selectivity of your compounds? Join our DUBprofiler Open Access Initiative & submit non-proprietary DUB modulators for screening against our gold standard #assay before 31 Jan. 💻 📩 services@ubiquigent.com
0
1
2
📢Ubiquigent launches DUBprofiler Open Access Initiative.Many #DUB inhibitors in the public domain have inadequately characterised selectivity. To counter this, we're inviting scientists to submit non-proprietary compounds for characterisation at no cost:
0
2
4
@AcceleroB Using DUBprofiler-Cell and DUBprofiler-Tissue, we supported a partner to determine target engagement & selectivity of their compound in biochemical, cell-based and preclinical animal studies. 📄Read more:
0
0
0
@AcceleroB 🏆@VincereBio was awarded a $500k grant from @MichaelJFoxOrg and received the NINDS SBIR Phase I award for its project ‘In vivo evaluation of USP30 inhibitors in models relevant to Parkinson’s disease’.
0
0
1
@AcceleroB 💰 Earlier in the year, @MISSIONTherapeu received funding from @MichaelJFoxOrg and @ParkinsonsUK to advance MTX325 through clinical trials. The USP30 inhibitor offers a potential treatment for early-stage Parkinson’s disease.
0
0
0
It’s great to see more and more exciting companies working in the DUB space!. 🤝 Mid-Atlantic BioTherapeutics and @AcceleroB combine neurological #drugdiscovery and high-throughput protein X-ray crystallography based fragment screening to develop USP30 inhibitors for Parkinson’s.
3
0
1
We had a great time at #BIOEurope Autumn! 🍂. In case you missed us, there’s still time to schedule a meeting during the virtual partnering event on 12-13 November – contact us at info@ubiquigent.com to find out more. #DrugDiscovery #DrugDevelopment #Pharma #Biotech #DUB
0
0
1
At Ubiquigent, we are accelerating our partners’ DUB-focused drug discovery programmes across core therapeutic areas, using our comprehensive suite of assays to identify and characterise novel DUB-modulating compounds: #USP30 #DUBs #DrugDiscovery.
0
0
0
USP30 is a DUB enzyme which is an actionable drug target for diseases associated with mitochondrial dysfunction, including Parkinson’s disease, with many companies exploring opportunities for USP30 inhibition.
1
1
4
#BIOEurope has kicked off, bringing together industry leaders to discuss the future of biotech. Our team have a busy week ahead, meeting with partners, customers, and potential investors to share insights into our novel approach to DUB-focused #drugdiscovery.📩info@ubiquigent.com
0
0
1
Next week, Hozefa Amijee and Rishi Shah will be at #BIOEurope,discussing how we are using our industry-leading platform to build a portfolio of novel DUB-targeting compounds to accelerate our partners’ programmes. Learn more:.💻📩 Info@ubiquigent.com
0
0
1
We’re delighted to be partnering with @AlleoLabs to accelerate DUB-focused drug discovery!. This collaboration will combine Alleo’s AI-based platform with our expertise in the DUB space to advance DUB-focused preclinical programmes. ➡
0
2
3
@IcahnMountSinai To find out more about how we are using our DUB-focused drug discovery platform to develop novel DUBTACs, get in touch: info@ubiquigent.com. #DUBTACs #ubiquitin #oncology.
0
0
0
🧾Novel DUBTACs to stabilise cGAS!. Researchers at @IcahnMountSinai have generated a novel #DUBTAC to stabilise cGAS, causing activation of downstream signalling and suppression of #cancer cell growth and colony formation. Read more:
1
0
3
🔔 Last chance to take advantage of our anniversary sale!. Join us in celebrating 15 years of supporting researchers with a minimum 15% discount on all orders of our custom ubiquitin proteasome reagents until 31 Aug. 💻 📩 sales.support@ubiquigent.com
0
0
0